PharmaMar announces abstracts to be presented at ASCO 2023

PharmaMar (MSE:PHM) has announced today that the Company and its partners will present seven new abstracts from several clinical trials with Zepzelca® (lurbinectedin) and Yondelis® (trabectedin) at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA. The studies to be presented at the congress include two oral presentations with two PharmaMar compounds. With the abstract entitled: “Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)“, Gregory Cote, MD, PhD, medical oncologist at Massachusetts General Hospital, will present updated efficacy and tolerability data on the combination of lurbinectedin with doxorubicin from the phase 1B soft-tissue sarcoma study leading into a randomized phase II trial in leiomyosarcoma (LMS). Peter Reichardt, MD, Physician-in-Chief of the Interdisciplinary Oncology Clinic HELIOS Klinikum Berlin-Buch, will present the abstract entitled: “Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)“, in which he will present efficacy and safety data of trabectedin plus nivolumab as second-line treatment for patients with metastatic or inoperable soft tissue sarcoma, previously treated with anthracyclines. The study confirms the activity of trabectedin plus nivolumab, particularly in patients with lipo- or leiomyosarcomas, suggesting synergistic activity. In addition, the safety of trabectedin and nivolumab was consistent with the safety profiles of each drug separately, with no new findings relevant to the combination. All ASCO poster presentations are available on request to registered participants for 180 days from May 26, 2023: https://asco.org/abstracts Highlighted studies at ASCO 2023 PRODUCTTITLELEAD AUTHORABSTRACT Zepzelca® (lurbinectedin)Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)Gregory CoteABSTRACT: 11507 SESSION TYPE: Oral Abstract Session S100a   DATE: June 5, 2023 11:30 – 14:30 GMT-5 Zepzelca® (lurbinectedin)Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLCSophie CousinABSTRACT: 8591 SESSION TYPE: Poster Session   POSTER: 218   DATE: June 4, 2023 8:00 – 11:00 GMT-5 Zepzelca® (lurbinectedin)A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator’s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)Benjamin BesseABSTRACT: TPS8613 SESSION TYPE: Poster Session   POSTER: 233a   DATE: June 4, 2023 8:00 – 11:00 GMT-5 Zepzelca® (lurbinectedin)IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU)Nicolas GirardABSTRACT: 8584 SESSION TYPE: Poster Session   POSTER: 211   DATE: June 4, 2023 8:00 – 11:00 GMT-5 Yondelis® (trabectedin)Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)Peter ReichardtABSTRACT: 11500 SESSION TYPE: Oral Abstract Session S100a   DATE: June 5, 2023 11:30 – 14:30 GMT-5 Yondelis® (trabectedin)SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES)Patrick GroharABSTRACT: 11519 SESSION TYPE: Poster Discussion Session   POSTER: 453   DATE: June 3, 2023 16:30 – 18:00 GMT-5 Yondelis® (trabectedin)Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA)Silvia StacchiottiABSTRACT: 11571 SESSION TYPE: Poster Session   POSTER: 505   DATE: June, 2023 13:15 – 16:15 GMT-5

The release as fetched from its publisher. pharmamar.com ↗